- Home
- ERAS vs ACHC Comparison
ERAS vs ACHC Comparison
Compare ERAS & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERAS | ACHC |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ERAS | ACHC |
|---|---|---|
| Price | $15.99 | $24.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | $11.38 | ★ $21.64 |
| AVG Volume (30 Days) | ★ 4.2M | 3.3M |
| Earning Date | 03-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.23 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,312,769,000.00 |
| Revenue This Year | N/A | $5.08 |
| Revenue Next Year | N/A | $5.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 5.04 |
| 52 Week Low | $1.01 | $11.43 |
| 52 Week High | $16.14 | $31.04 |
Technical Indicators
Market Signals| Indicator | ERAS | ACHC |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 62.82 |
| Support Level | $1.50 | $23.02 |
| Resistance Level | $16.14 | $25.07 |
| Average True Range (ATR) | 1.09 | 1.20 |
| MACD | -0.12 | -0.38 |
| Stochastic Oscillator | 87.52 | 59.90 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.